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RAC opinionIn 2012 the Committee for Risk Assessment (RAC) of the European Chemicals Agency concluded that
2 ppm formaldehyde represent a Lowest Observed Adverse Effect Concentration (LOAEC) for polypoid
adenomas, histopathological lesions and cell proliferation. An analysis of all data shows that a LOAEC
of 2 ppm it is not justiﬁed for cell proliferation and polypoid adenomas. Higher values are also supported
by a new statistical analysis. For histopathological lesions a NOAEC of 1 ppm may be deﬁned but the
lesions at 2 ppm cannot be regarded as pre-stages for tumour development. One major uncertainty
exists: the description of polypoid adenomas and the lesions at 2 ppm often is insufﬁcient and diagnostic
uncertainties can only be resolved by a re-evaluation according to modern histomorphological standards.
Although the discrepancy between our assessment and that of RAC may seem rather small we feel the
LOAECs proposed by RAC must be challenged taking into consideration the broad data base for formalde-
hyde and the potential impact of any published RAC opinion on the present discussions about appropriate
occupational and indoor exposure limits.
 2014 The Authors. Published by Elsevier Inc. This is anopenaccess article under theCCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
On November 30, 2012 the Committee for Risk Assessment
(RAC) of the European Chemicals Agency (ECHA) adopted an opin-
ion proposing the harmonised Classiﬁcation and Labelling (C&L) at
the EU level for formaldehyde (FA). This opinion is now available
on the ECHA website (RAC, 2012).
Decisions on C&L are strictly hazard based. Nevertheless, this
opinion contains a variety of statements deﬁning Lowest Adverse
Effect Concentrations (LOAECs) that are of minor relevance for such
a hazard assessment but may have an important bearing on risk
based decisions like setting exposure limits. If LOAECs are identi-
ﬁed by RAC as a highly respected and inﬂuential scientiﬁc body,
its opinion must take into consideration the whole database to
ﬁnally arrive at a well-balanced evidence based decision.
For three different endpoints the RAC opinion concluded that
the LOAECs were 2 ppm, namely for cell replication, histopatholo-
gical alterations and tumour response (polypoid adenomas), all
discussed as being related to the development of nasal tumoursin rats that were pivotal for arriving at the cat. 1B classiﬁcation
proposal. While we do not contest this classiﬁcation proposal here,
we want to challenge the LOAECs proposed by the RAC. We are of
the opinion that the total database available has not been taken
into consideration by the RAC in a scientiﬁc defensible manner.
We submitted our comments and arguments to the RAC but
unfortunately they are neither reﬂected nor refuted in the opinion
published. Therefore we want to take the opportunity to present
basically the same arguments to the scientiﬁc community to
stimulate a discussion on this issue. We will discuss the scientiﬁc
literature available for these three endpoints and present new sta-
tistical analyses for cell replication and tumour response (polypoid
adenomas) showing that the data do not justify the conclusion of
2 ppm being a LOAEC.2. LOAEC for tumour response (polypoid adenomas, PA)
According to RAC (2012) 2 ppm is proposed as a LOAEC for
tumour response (papillomas, polypoid adenomas) here summa-
rized as PA. It is mentioned that ‘‘the study of Kerns et al. (1983)
revealed increased rates of benign nasal tumours (papillomas, pol-
ypoid adenomas) from 2 ppm onwards’’ (p. 14) and ‘‘both the pres-
ence of papillomas (the benign type of squamous cell tumours) and
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found. It is further pointed to an ‘‘. . . adenomatous polyp . . . after
18 months of formaldehyde exposure to 2 ppm (Swenberg et al.,
1980)’’ (p. 16). And it is stated (p.44) that ‘‘benign squamous cell
tumours were seen at 2 ppm. Nasal tumours were not seen in
any of the internal control groups of the animal studies.’’
A conclusion about the LOAEC for this tumour type must be
based on an in depth assessment taking account of the following
points:
 Consistency of histomorphological diagnostic criteria and diag-
noses in different studies.
 Are PA related to exposure to FA?
 Is PA a tumour type on its own or related to SCC?
 Assessment of the incidences of PA in the study of Kerns et al.
(1983).
 A new statistical analysis of the PA incidences.
2.1. Consistency of histomorphological diagnostic criteria and
diagnoses
In Table 25 (p. 11) of the RAC report the tumour incidences are
given. In this table the diagnostic ﬁndings ‘‘Polyps, papillomas or
polypoid adenomas’’ are grouped together implicating a common
precursor lesion for squamous cell carcinomas (SCC). A clear differ-
entiation has to be made between papillomas and polypoid adeno-
mas, because only a papilloma might progress to a SCC, whereas
the malignant counterpart of a polypoid adenoma is not a SCC,
but an adenocarcinoma, with distinct morphological differences
to SCC. Adenocarcinomas are not the tumour type associated with
FA. Only Kerns et al. (1983) gave a detailed morphological descrip-
tion and thereby the alterations found in his study are to be
regarded as polypoid adenomas that might ultimately progress to
adenocarcinomas that were not observed in this study. Feron
et al. (1988), Woutersen and Feron (1989), Monticello et al.
(1996) and most probably also Woutersen et al. (1989) followed
the diagnostic criteria of Kerns et al. (1983). In the papers of
Kamata et al. (1997) and Sellakumar et al. (1985) a detailed mor-
phological description of the papillomas (Kamata) and polyps
and papillomas (Sellakumar) they found is missing. Kamata called
them ‘‘squamous cell papilloma’’, which indicates a different mor-
phology than PA. Sellakumar grouped polyps and papilloma
together, which makes it impossible to differentiate between both
entities. To differentiate, diagnose and classify all relevant or ques-
tionable preneoplastic precursor lesions and benign neoplasms
found in the different studies a pathology peer review of all rele-
vant histopathological slides should be performed. The Pathology
Peer Review has to be done by one experienced toxicopathologist
followed by a PWG (PathologyWorking Group) using the standard-
ized and harmonized internationally-accepted nomenclature
according to the published INHAND (International Harmonization
of Nomenclature and Diagnostic Criteria for Lesions in Rats and
Mice) project (Renne et al., 2009). Generally, only when the
relevant histopathological ﬁndings are diagnosed with identical
criteria and nomenclature, they can be used as a common basis
for scientiﬁc judgement and setting of reasonable LOAECs/NOAECs.
2.2. Are PA related to exposure to FA?
To decide on this question the incidences of PA and PA-like neo-
plasms in different studies are summarized:
Kerns et al. (1983), Battelle (1981): Male and female F344 rats
were exposed to FA over 24 months with a post exposure period
of up to 6 months. At the 18 month interim sacriﬁce the term ‘‘ade-
nomatous polyp’’ was used that was later changed to ‘‘polypoid
adenoma’’. The total incidences of PAs at 0, 2.0, 5.6 and 14.3 ppmwere for male rats 1/118, 4/118, 6/119, 4/117 and for female rats
0/114, 4/118, 0/116, 1/115.
Sellakumar et al. (1985): Male Sprague Dawley rats were
exposed over lifetime (about 128 weeks) to 0 ppm (each one cham-
ber and one animal room control group), 10 ppm HCl, 14 ppm FA,
10 ppm HCl + 14 ppm FA (premixed), 10 ppm HCl + 14 ppm FA
(not premixed). The group sizes were 99 and 100 rats. Papillomas
and polyps were grouped together without further description.
These neoplasms were observed at incidences of 10/100, 13/100,
11/100 in the FA, HCl + FA (premixed), and HCl + FA (not premixed)
groups. No such tumours were observed in both of the control
groups (0/99, each) and under HCl exposure (0/99).
Kamata et al. (1997): Male F344 rats were exposed over
28 months to 0, 0.3, 2 and 15 ppm. The PA like lesion was termed
as ‘‘squamous cell papilloma’’ without giving diagnostic criteria.
The ﬁrst one was noted at the 18 month interim sacriﬁce in 1/5
animals examined. In total 3/32 animals developed such papillo-
mas at 15 ppm (2 additional incidences in animals found dead dur-
ing the study) and none was found at the lower exposure levels.
Feron et al. (1988) and Woutersen and Feron (1989): Both publi-
cations describe the same experiment in which male Wistar rats
were exposed to 0, 10 and 20 ppm FA over 4, 8, and 13 weeks fol-
lowed by an exposure free period leading in total to 126 weeks of
the experiment. The group size examined was 43–45 animals and
the diagnostic criteria of Kerns et al. (1983) were used for PAs. One
PA was observed each at 20 ppm exposure over 4 and 8 weeks but
not after 13 weeks of exposure. A further PA is mentioned after
13 weeks of FA exposure at 10 ppm by Woutersen and Feron
(1989) but not by Feron et al. (1988).
Woutersen et al. (1989): Male Wistar rats were exposed over
28 months or over 3 months (followed by a 25 month post expo-
sure period) to 0, 0.1, 1 and 10 ppm FA. Subgroups were used with
undamaged and damaged nasal epithelium by electrocoagulation
directly before FA exposure. The group size was 60 animals with
damaged nose and 30 with undamaged. Only 1 PA was found in
the group with undamaged nose and 3 months of exposure at
10 ppm. It is questionable whether this PA was induced by FA
exposure (or rather represented a spontaneous lesion) because
continuous exposure over 28 months did not lead to PAs in animals
with damaged or undamaged nose.
Monticello et al. (1996): male F344 rats were exposed up to
24 months at 0, 0.7, 2, 6, 10, and 15 ppm. 5/90 animals developed
PAs at 10 ppm and 14/147 at 15 ppm that were similar in nature as
described by Kerns et al. (1983) and in location according to
Morgan et al. (1986). In the lower exposure groups no PAs were
found with 90 or 96 animals/group.
These data show that FA at sufﬁciently high exposures may lead
not only to SCC but also to PAs or PA like neoplasms. But as in some
of these publications a histomorphological description is missing, a
decision cannot be made whether all the lesions observed corre-
sponded to the PAs described originally by Kerns et al. (1983).
2.3. Is PA a tumour type on its own or related to SCC?
Obviously, RAC (2012) is of the opinion that PA and PA-like
lesions are related to the development of SCC as indicated by their
statements: ‘‘papillomas (the benign type of squamous cell
tumours)’’ or ‘‘benign squamous cell tumours were seen at
2 ppm‘‘. In addition, referring to Kerns et al. (1983) it is said that
both papillomas and polypoid adenomas are found at 2 ppm.
First of all it has to be clariﬁed that Kerns et al. (1983) did not
diagnose any papilloma, but only polypoid adenomas.
Basically polypoid adenomas and papillomas should not be
merged under today’s terms of deﬁnition, because they may pro-
gress into different tumour types (adenocarcinoma or squamous
cell carcinoma, respectively) and a clear differentiation is necessary,
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experts with consistent diagnostic criteria (Renne et al., 2009).
According to the detailed laboratory report (Battelle, 1981) of
the Kerns study, the terms adenomatous polyp and polypoid ade-
noma describe the same lesion. Up to the 18 month interim sacri-
ﬁce the term ‘‘adenomatous polyp’’ was used by Battelle (1981)
and later changed to PA. This explains why in the 18 month interim
publication Swenberg et al. (1980) describe an ‘‘adenomatous
polyp’’ that was listed later by Kerns et al. (1983) as PA. Obviously,
RAC is of the opinion that the PAs represent a benign type of squa-
mous cell tumours but no reference is given in support. We did not
ﬁnd in the literature any indication that PA can be regarded as
benign pre-stages of SCC. This is also supported by the fact that
no tumours were described in the studies of Kerns et al. (1983)
and Monticello et al. (1996) that exhibited at the same time mor-
phological features of PA and SCC. In contrast, Kerns et al. (1983)
expressively stated that ‘‘there was no evidence of progression
from PA to SCC’’. In addition, according to Kerns (1985) ‘‘no evi-
dence is available to suggest that polypoid adenomas progress to
adenocarcinomas of the nasal cavity in the rat’’.
As regards the location, many PAs and SCCs are located in or
adjacent to the lateral meatus (Monticello et al., 1996; Morgan
et al., 1986). But PA are ‘‘conﬁned to a small ‘‘locale’’, which is nor-
mally lined by nonciliated cuboidal and sparsely ciliated columnal
epithelia’’. For SCCs the sites of origin ‘‘are normally lined by respi-
ratory epithelium’’ (Morgan et al., 1986). And most importantly,
the PAs in ‘‘rats exposed to 0, 2.0 and 5.6 ppm of FA were not asso-
ciated with zones of epithelial dysplasia or squamous metaplasia’’
(Kerns et al., 1983). These latter alterations are to be regarded as
pivotal pre-stages to the development of SCC and they are the ﬁrst
lesions developing after FA exposure. All these ﬁndings represent
important arguments that PA must not be taken together with
SCC but must be assessed separately even if PA may be related to
FA exposure at high concentrations. Speciﬁcally the PAs at 2.0
and 5.6 ppm in the Kerns study might not have any association
at all with SCC development and at these exposures (including
0.7 ppm) no PAs were found by Monticello in a 2-year study with
90 male rats/group.
Thus, the morphological description alone of PAs and similar
lesions do not allow evidence based decisions whether these
ﬁndings may be interpreted as direct precursors of SSC. Only a
reanalysis of tissues by a PWG using today’s diagnostic criteria
could help in this respect. But differences in location of PA and
SCC as well as different epithelial origin speak against an obvious
interrelationship of both tumour types.
2.4. Assessment of the incidences of PA in Kerns et al. (1983)
The statistical analysis of PAs in Kerns et al. (1983) showed that
‘‘when adjusted and unadjusted data were analysed, no signiﬁcant
differences were observed in pairwise analyses; however, a signif-
icant adjusted trend (p < 0.05) was present for male rats‘‘. This
pairwise statistical analysis may be taken as an indication that
2 ppm (and even 6 ppm) is a NOAEC what is also strongly sup-
ported by Monticello et al. (1996).
In addition the spontaneous occurrence of such lesions has to be
taken into consideration as has been done by Swenberg et al.
(1983): ‘‘This lesion has been found at a frequency similar to that
observed in the CIIT controls when control rats of other studies
have been subjected to a thorough evaluation of the nasal pas-
sages. [Recent bioassays of the National Toxicology Program and
Dow Chemical Company have demonstrated several control groups
of 50–60 F-344 rats with at least one polypoid adenoma or adeno-
carcinoma.]’’ Unfortunately, no detailed numerical data have been
reported to support this statement but Lomax et al. (1997) men-
tioned a contemporary study of Miller et al. (1985) where polypoidadenomas were observed in 1/60 male and 1/59 female control
rats. This seems to be in contrast to the NTP (2013) historical
database provided that preparation of nasal tissue specimen was
comparable to that followed in the studies with FA. In the NTP
database about 25 inhalation studies are listed with F344 rats
and no PAs were observed in control groups.
Finally, the statement of RAC (2012) that ‘‘nasal tumours were
not seen in any of the internal control groups of the animal stud-
ies’’ is incorrect as one PA was observed in the concurrent male
rat control group of the Kerns study. Furthermore, even SCC have
been found in an internal control group by Feron et al. (1988): In
this study, three groups of rats were kept in the inhalation
chamber at 0 ppm FA for 4, 8, or 13 weeks and thereafter the
in the animal room up to 130 weeks. The respective incidences of
SCC were 0/44, 2/45 (4.4%) and 0/45. In addition, Woutersen
et al. (1989) observed one SCC in 26 rats exposed to 0.1 ppm over
28 months. It is highly probable that this tumour is of spontaneous
origin and not related to FA, as SCC have never been observed at
such low concentrations.2.5. Statistical analysis of the PA incidences
An additional statistical analysis has been carried out to con-
clude about the NOAEC/LOAEC for polypoid adenomas (see Online
Appendix 1). The data of Kerns et al. (1983) were analysed for male
and female rats separately and combined. In addition the inci-
dences reported by Monticello et al. (1996) for male rats were
added. A trend analysis and a binary comparison by logistic regres-
sion were carried out. Thereby no signiﬁcant trend but a signiﬁcant
increase from 0 to 2 ppmwas found among all rats. Thus, the state-
ment of Kerns et al. (1983): ‘‘no signiﬁcant differences were
observed in pairwise analysis, however a signiﬁcant adjusted trend
(p < 0.05) was present for male rats’’ (Kerns et al., 1983, p.4385)
could not be conﬁrmed. Adding the Monticello et al. (1996) data
did not clarify the dose response. The analyses are difﬁcult because
the sparse data in the control group (0 ppm: only 1 male case
among 240 rats) leads to data instability. The Monticello results
did not change this situation because no polypoid adenomas
occurred in the control and low dose groups either. Such a situa-
tion renders subgroup analyses (male, female) almost impossible
and p-values and risk estimates are potentially distorted
(Greenland et al., 2000): p-values are potentially too small and rel-
ative risk estimates are too high. This distortion due to the sparse
data bias may be the reason that the results published by Kerns
et al. (1983) could not be conﬁrmed.
To adjust for the sparse data bias a Laplace – de Morgan correc-
tion was applied: adding 1 to all cells of cases and non-cases (with-
out renormalization) (Subbiah and Srinivasan, 2008; Greenland
et al., 2000). Thereby no signiﬁcant ﬁndings, neither for trend nor
in the comparison of 2 vs. 0 ppm were found after applying the
Laplace – de Morgan correction, neither for the Battelle/Kerns data
alone nor for the combination with the Monticello data. The data
appear to be too weak to justify a conclusion about the expo-
sure–response relationship between formaldehyde exposure and
the occurrence of polypoid adenomas in Fischer rats. In particular,
there is no reliable evidence of any increase in risk across the inter-
esting exposure range up to 6 ppm and, thus, a NOAEC of at least
2 ppm seems to be compatible with the data best available.
Because no exposure–response relationship could be identiﬁed it
is obvious that no NOAECs or LOAECs could be estimated. Indeed,
the likelihood proﬁle from hockey-stick modelling returned maxi-
mal chi2(df = 1)-values always lower than 0.6 (p = 44%), i.e. clearly
insigniﬁcant, even at the highest concentration of 15 ppm (see for a
detailed explanation of this approach the application in Section 4.2.
Statistical analysis of the cell proliferation data).
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centrations (P10 ppm) will not only lead to SCC but also to PA.
Whether PA is to be considered a tumour type distinct from SSC
cannot be unequivocally decided by the data available so far. The
location and interpretation given by Kerns et al. (1983) tend to indi-
cate separate entities but the histomorphological descriptions in all
the publications do not enable a clear decision. Only a re-evaluation
of the slides may lead to clariﬁcation. Regarding the incidences of
PA at lower concentrations (66 ppm), the original statistical analy-
sis of Kerns et al. (1983) did not allow a ﬁrm conclusion. Historical
data of the NTP indicate that the incidence of this tumour type is
extremely low but Swenberg et al. (1983) concluded that PA may
occur spontaneously more often than generally assumed provided
that the protocols followed procedures of comparable detail. By a
new statistical analysis reliable NOAECs/LOAECs could not be
derived for an exposure range up to 6 ppm and, thus, a NOAEC of
at least 2 ppm cannot be ruled out by the data available.3. LOAEC for histopathological alterations
According to the RAC opinion 2 ppm is proposed as a LOAEC for
histopathological alterations taken as early tumour precursors. It is
stated (p. 14): ‘‘Signs of inﬂammation and regenerative prolifera-
tion (nasal epithelial hyperplasia) in the nasal cavity are also
observed in studies from 2 ppm. Dysplasia of nasal epithelia that
may indicate transformation to early precursor tumour cells were
also seen from 2 ppm onwards’’ and ‘‘taking putative precursor
lesions and benign tumours into account the LOAEC for neoplastic
and corresponding preneoplastic/benign tumour responses is
2 ppm.’’ On page 16 further studies are referenced for support:
‘‘the evidence of epithelial hyperplasia observed at the same con-
centration (2 ppm) (Kamata et al., 1997)’’ and ‘‘epithelial dysplasia
(35/40 rats), squamous metaplasia (24/40 rats) and adenomatous
polyp (1/40) (the latter two effects require cell proliferative activ-
ity in their development) after 18 months of formaldehyde expo-
sure to 2 ppm conﬁrmed LOAEC of 2 ppm (Swenberg et al.,
1980)’’ and ‘‘the LOAEC of 2 ppm was also supported by other
recent studies (Andersen et al., 2008, . . . Andersen et al., 2010
. . .) who found nasal lesions . . . at 2 ppm and higher.’’
In Table 25 (p. 11) RAC has summarized the histopathological
changes of different investigations. Only those at exposure concen-
trations up to 6 ppm are reproduced here in Table 1. RAC differen-
tiated between lesions ‘‘reported as absent’’ and those ‘‘not
reported’’. It is unclear whether this differentiation may have any
meaning for an assessment, but generally it can be assumed that
a lesion not reported actually was not observed.
The interpretations by RAC should be discussed under two
aspects:
1. Do the ﬁndings observed at 2 ppm ‘‘indicate transformation to
early precursor tumour cells’’?
2. If 2 ppm is a LOAEC for histopathological alterations in long
term studies, can a NOAEC be deﬁned?Table 1
Histopathological lesions reported by RAC up to 6 ppm.
Signs of chronic irritation Exposure concentration (ppm)/Autor
0.1/W 0.3/Ka 0.7/M
Epithelial cell hyperplasia  + 
Epithelial dysplasia NR NR 
Squamous cell metaplasia  + 
Rhinitis   
Cell inﬁltration NR  
Edema NR  
W: Woutersen et al. (1989); Ka: Kamata et al. (1997); M: Monticello et al. (1996); Ke: K3.1. Do the ﬁndings at 2 ppm represent neoplastic precursors?
In order to clarify this question 2 points should be discussed:
a. The location of the lesions at low exposures in relation to
that of the SCCs at higher exposures.
b. The histomorphological features.
Ad a: The Kerns et al. (1983) study provides the most reliable
data in terms of number of experimental animals, interim sacri-
ﬁces and description of the location of the lesions. Their ﬁndings
were basically conﬁrmed by Andersen et al. (2008, 2010). In these
investigations histopathological alterations at 2 ppm were con-
ﬁned to level I for all time points and they were already observed
after 6 months by Kerns et al. (1983) or even earlier (Andersen
et al., 2008, 2010). The levels which are routinely trimmed and
embedded are as follows from anterior to posterior: level I: poster-
ior part of upper incisors, level II: incisive papilla, level III: second
palatine crest, level IV: ﬁrst molar teeth. Nevertheless, depending
on anatomical variations in different rat strains and special inves-
tigations, slight differences of the cut level may occur.
To decide whether the lesions at 2 ppm are to be regarded as
pre-stages to the development of SCC, their locations must be com-
pared to each other. The location of SCC was analysed by Morgan
et al. (1986). 57% of SCC originated form level I and II and 25% from
level II and III at 15 ppm. At 5.6 ppm one of both of the SCC derived
from level II and the other one from level III. But the alterations at
2 ppm were strictly conﬁned to level I. They were more prominent
and developed earlier in the course of exposure than those at level
II at 5.6 ppm. If the lesions at 2 ppm were pre-stages of SCC, these
tumours should predominantly coincide with the location at level I
which was not the case. In addition, the origin of both of the SCC at
5.6 ppm did not coincide with the location of the lesions at 2 ppm.
Thus, the location of the histopathological alterations at 2 ppm is
clearly different from the most sensitive part of the nose for
tumour development and they cannot be regarded as direct prene-
oplastic precursors.
Kamata et al. (1997) already reported ﬁrst lesions at 0.3 ppm.
They differentiated between non-proliferative lesions that were
statistically signiﬁcantly increased at 2 ppm and proliferative
lesion that were numerically increased at 0.3 ppm and signiﬁcantly
at 2 ppm. But the description of the location is less clear than that
in the studies of Kerns et al. (1983). Kamata et al. (1997) found
most of the non-proliferative lesions at levels B and C correspond-
ing more or less to levels I and II of Kerns et al. (1983). For the pro-
liferative lesions the location is not given and the nasal tumours
were located at levels B and C similar to the non-proliferative
lesions. But a clear assignment of the number of histopathological
lesions observed with regard to their locations is missing and
therefore a decision whether the proliferative lesions are pre-
stages of SCC is not possible.
Ad b: Of all the studies cited in this respect by RAC, Kerns
et al. (1983) provided the most detailed description of the1/W 2/M 2/Ka 2/Ke 5.6/Ke 6/M
  +   
NR NR NR + + NR
  + + + +
  + + + NR
NR   NR NR NR
NR   NR NR NR
erns et al. (1983); +: reported as present; : reported as absent; NR: not reported.
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thelial dysplasia’’ and ‘‘squamous metaplasia’’ it becomes obvious,
that the term ‘‘epithelial dysplasia’’ is not a tumour precursor per
se as stated by RAC but just another term for ‘‘squamous metapla-
sia without keratinization’’. Therefore it cannot be concluded that
the epithelial lesions (including squamous metaplasia with or
without keratinization) at 2 ppm are adverse per se and direct pre-
cursors of SCC, but they might rather be interpreted as a physiolog-
ical adaptive response to chronic exposure. The ﬁndings of Kerns
et al. (1983) are supported by the most recent study of Andersen
et al. (2010) after 13 weeks of exposure with squamous metaplasia
only at 2 ppm at level I while no such alterations were observed at
level II. After 3 weeks of exposure apart from inﬂammatory inﬁl-
trates, treatment related squamous metaplasia occurred only at
6 ppm, while some animals developed epithelial hyperplasia at
2 ppm (Andersen et al., 2008). In contrast, no treatment related
histopathological nasal lesions were reported at 2 ppm after
6 weeks (Monticello et al., 1991) and 2 years of exposure, ‘‘while
lesions at 6 ppm were minimal or absent’’ (Monticello et al.,
1996). But the extent to which level I was investigated by Monti-
cello seems unclear as in the 6 week study only the ﬁndings at
level II and III were presented. Using a similar approach for section-
ing the nasal cavity no histopathological alterations were noted up
to 6 ppm after 4 weeks (Speit et al., 2011).
Somewhat divergent ﬁndings were described by Kamata et al.
(1997). At 2 ppm they observed squamous metaplasia (without
epithelial cell hyperplasia) as a non-proliferative lesion and epithe-
lial cell hyperplasia (with squamous cell metaplasia) as a prolifer-
ative lesion. The incidence of the non-proliferative lesion, as
deﬁned by the authors, was statistically signiﬁcantly increased at
2 ppm and that of the proliferative lesion numerically at 0.3 ppm
and signiﬁcantly at 2 ppm. Apart from these terms no description
deﬁning these lesions is given. Only one photograph is presented
for squamous cell metaplasia without epithelial hyperplasia at
2 ppm and one for hyperplasia with squamous cell metaplasia only
at 15 ppm. Thus the extent especially of the latter lesions deﬁned
as proliferative at lower concentrations remains unclear.
The different ﬁndings of Kerns et al. (1983) and Kamata et al.
(1997) and the open questions concerning the Kamata study can
only be clariﬁed by a reassessment of the slides and terminology.
The lesions should be deﬁned according to today’s criteria by a
pathology review and their location exactly speciﬁed in order to
decide on their possible relationship with SCC.
In general, squamous metaplasia sometimes occurs in associa-
tion with chronic inﬂammation or in the process of regeneration.
Squamous metaplasia with a normal maturation pattern may be
reversible under some experimental circumstances (e.g., depending
on nature of inhaled irritant and duration of exposure) but in other
situations may eventually give rise to squamous cell papilloma or
squamous cell carcinoma. Additionally, epithelial hyperplasia is fre-
quently a reversible alteration whereas under certain circum-
stances hyperplasia might be preneoplastic (Renne et al., 2009).
3.2. Can a NOAEC for histomorphological changes be deﬁned?
A deﬁnition of a LOAEC, taken by RAC as 2 ppm for histopathol-
ogical alterations in the nose, should be accompanied by a discus-
sion of a possible NOAEC. But this is missing in RAC (2012). The
lesions at 2 ppm occurred after 6 months only in a low incidence
(10%) in the study of Kerns et al. (1983) and reached 35% and
100% with prolonged exposures of 1 and 2 years. Therefore for
deﬁning a NOAEC, only investigations with an exposure duration
of at least 6 months may be used. Rusch et al. (1983) exposed 6
male Cynomolgus monkeys, 20 male and 20 female Fischer 344
rats and 10 male and 10 female Syrian golden hamsters at 0,
0.19, 0.98 and 2.95 ppm FA (22 h/d, 7 d/week over 26 weeks). Inrats and monkeys nasal lesions were found at 2.95 ppm with a
NOAEC of 0.98 ppm. In hamsters the NOAEC was 2.95 ppm. Simi-
larly, no nasal lesions were observed at 1 ppm by Appelman
et al. (1988) in 10 male Wistar rats exposed over 1 year or by
Woutersen et al. (1989) in 28 male Wistar rats exposed over
28 month (each 6 h/d, 5 d/week). Thus the NOAEC for rats and
monkeys is 1 ppm, a conclusion already reached by Nielsen and
Wolkoff (2010).
But in the study of Kamata et al. (1997) some histomorpholog-
ical alterations were already observed at 0.3 ppm, although not to a
statistically signiﬁcant extent, namely ‘‘epithelial cell hyperplasia
with squamous cell metaplasia’’ in 4/32 animals. Again the rele-
vance of this divergent ﬁnding can only be clariﬁed by a pathology
peer review.
In summary, histopathological lesions at 2 ppm were assumed
by RAC (2012) to be possible early tumour precursors. But in the
studies with the detailed descriptions alterations at 2 ppm were
strictly conﬁned to level I of the nose, while tumours developed
not only at this level but also at more distant sites. Speciﬁcally
the SCC at 5.6 ppm derived from level II and III. In addition, the
detailed histomorphological description showed that these lesions
should rather be interpreted as a physiological adaptive response.
Therefore, the lesions at 2 ppm cannot be regarded as a preneo-
plastic event based on the most comprehensive study of Kerns
et al. (1983) although there are conﬂicting observations reported
by Kamata et al. (1997). Because of missing details in this publica-
tion only a peer pathology review could resolve these discrepan-
cies and arrive at a deﬁnitive conclusion. By comparison with
other studies with sufﬁcient exposure duration a NOAEC of
1 ppm can be derived. But again some open questions remain with
the study of Kamata et al. (1997).4. LOAEC for cell proliferation
According to the RAC opinion, 2 ppm is proposed as a LOAEC for
cell proliferation as stated for example: ‘‘. . . the LOAEC for
increased cell replication was already reached at 2 ppm’’ or
‘‘. . .2 ppm is the LOAEC for increased cell proliferative activity’’
(both p. 16) or ‘‘taking the LOAEC for increased cell proliferation/
precursor lesions of 2 ppm’’ (p.18) and ‘‘data also indicate non-sig-
niﬁcant dose-related increases in cell proliferative activity. . .
below 2 ppm’’ (p.19).4.1. Indices for cell proliferation and available data
Such statements on the LOAEC require an assessment of all
important studies on cell proliferation. In the RAC opinion the con-
clusion that 2 ppm is the LOAEC for cell proliferation is solely based
on the interpretation of Fig. 6 from the study of Meng et al. (2010)
that is reproduced on p. 15 of the RAC opinion.
The cell proliferation data in the Meng study is only a subset of
those described by Andersen et al. (2010) who exposed rats to 0,
0.7, 2, 6, 10, and 15 ppm over 1, 4, and 13 weeks. Cell proliferation
was determined at several sites of nasal level I, II, and III, but only
those at level I and level II (alm – anterior lateral meatus) are
reported. Level I, although the region with the highest impact (ﬂux)
of FA on the lining epithelium, is not a prominent location of SCC,
while many SCC originate from the alm. The labelling index (LI;
labelled cells divided by total cells) and the unit length labelling
index (ULLI; labelled cells per length of base membrane) were cal-
culated. In the Andersen et al. (2010) paper ULLI is given for all
time points for level I and II (alm), and Meng reports LI only for
the subset of level II (alm) at week 13. It should be mentioned that
most investigations on cell proliferation reported ULLI and not LI
for cell proliferation. Statistically signiﬁcant differences between
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nett’s test (p < 0.05 and 0.01).
The RAC opinion proposes to use doubling of cell proliferation
(LI) derived from Fig. 6 of Meng et al. (2010) as a biological mean-
ingful response to deﬁne a LOAEC, even if not statistically signiﬁ-
cant. To arrive at a defensible conclusion about a NOAEC/LOAEC
for cell proliferation the whole data set given by Andersen et al.
(2010) should be taken into consideration and not only Fig. 6 of
Meng et al. (2010). That different indices for cell proliferation were
used in both publications is of minor importance because there is a
close parallelism between LI and ULLI as already described by
Monticello et al. (1990). Table 1 given by Andersen et al. (2010)
clearly shows the large standard deviations in relation to the
means for ULLI, for example at 0.7 and 2 ppm after 13 weeks of
exposure at the alm (29.7 ± 24.6 and 56.3 ± 33.3), corresponding
to the high variability of the LI data indicated by Fig. 6 of Meng
et al. (2010). In such cases it can hardly be justiﬁed to dismiss
the results of statistical analyses and base a decision solely on
the interpretation of a graph.
The data of Andersen et al. (2010) shows that at 2 ppm for week
1 and 4 there is no indication, not even for a numerical increase of
ULLI at level I or level II (alm), and due to parallelism of ULLI and LI
this should also be the case for LI. Only at week 13 and only for
level II the data can be interpreted as showing a prominent numer-
ical, but not a statistically signiﬁcant increase of ULLI.
Under such circumstances it can hardly be justiﬁed to decide on
LOAECs based only on one point in time and location and just on
numerical differences without taking into account the statistical
signiﬁcance and biological plausibility.
It is useful to compare the NOAECs for cell proliferation from
different publications as compiled in Table 2.
The most comprehensive investigation is that of Monticello
et al. (1996). No increase of cell proliferation was found up to
6 ppm and the most marked increase was noted for the anterior
lateral meatus (alm) and the medial maxilloturbinate (mmt). Over-
all, the magnitude of increased cell proliferation decreased over
exposure durations from 3 to 18 months. This time dependency
is also shown by comparison with Monticello et al. (1991). Here
a statistically signiﬁcant increase in cell proliferation was found
at 6 ppm after 1, 4 and 9 days and after 6 weeks of exposure with
a clear numerical decline after 6 weeks compared to the shorter
exposure durations. For the more prolonged exposure of
Monticello et al. (1990, 1996) no increase was noted with 6 ppm
after 3 months or longer. The time dependency of cell proliferation
is shown in Table 3 combining the data Monticello et al. (1991) and
Monticello et al. (1996). The clear difference of ULLI in both publi-
cations, e.g. at 0 ppm, is explained by the different approach for
nuclear labelling. Monticello et al. (1991) used pulse labelling by
a single ip injection of with [3H]thymidine 2 h before sacriﬁce
while Monticello et al. (1996) used an osmotic pump inserted over
5 days prior to sacriﬁce. The alm of Monticello et al. (1996) corre-
sponds to level II, site 1 of Monticello et al. (1991) and the mmt to
level II, site 3, respectively.
Wilmer et al. (1989) investigated whether FA induced cell pro-
liferation is related to the exposure concentration or to the total
dose. Male Wistar rats were exposed over 8 h/day for 3 days or
13 weeks (5 d/week) either continuously to 0, 1, or 2 ppm or to 2
or 4 ppm interruptedly (eight 30 min exposure periods separated
each by 30 min non-exposure periods). After 13 weeks of exposure
but not after 3 days there was an increase in cell proliferation (not
statistically signiﬁcant) in the 4 ppm (interrupted) exposure group,
but not in the group continuously exposed to 2 ppm although both
groups received the same total dose (ppm  h).
A different method for measuring cell proliferation was used by
Casanova et al. (1994). Male rats were exposed to 0, 0.7, 2, 6, and
15 ppm for 11 weeks (6 h/d, 5 d/week) plus 4 days to unlabeledFA. At the end of this period [14C]FA was given once for 3 h by nose
only exposure at the same concentrations as those used in the pre-
exposure phase. Nuclear [14C] content was taken as a quantitative
measure of cell proliferation as tissues with high levels of cell pro-
liferation incorporate relatively large amounts of FA into the DNA.
Tissue was sampled from the lateral meatus and the medial/pos-
terior meatus and the content of [14C] in DNA was determined. Cell
proliferation was induced at 6 ppm and especially at 15 ppm, but
not at 2 ppm.
Andersen et al. (2008) and Speit et al. (2011) are studies with
shorter exposure duration (3 and 4 weeks) and their results basi-
cally agree to those mentioned above.
Comparison of all studies measuring cell proliferation with dif-
ferent methods and exposure durations consistently shows a
NOAEC of 2 ppm and in many cases even of 6 ppm, in contrast to
the interpretation given in the RAC opinion based solely on the
numerical increase in a single subset of data reported by Meng
et al. (2010).
4.2. Statistical analysis of the cell proliferation data (ULLI, LI)
The Hamner Institute (Hamner, 2007) provided the individual
data on which the publications of Andersen et al. (2010) and
Meng et al. (2010) were based. An independent statistical analysis
was carried out based on these individual data for ULLI as used by
Andersen et al. (2010) and LI as used by Meng et al. (2010) for the
alm. Analysis was done by multivariable linear regression either
for all time points (1, 4 and 13 weeks) together or separately. The
analyses were performed with hockey stick linear regression mod-
els (Ulm, 1991) and the threshold regions were identiﬁed by like-
lihood proﬁle methods (Morfeld et al., 2006, 2013).
Estimation of the concentration threshold s was performed by
subtracting a series of candidate exposure concentration values
from the FA concentration data (setting the result to zero if nega-
tive), and rerunning the multiple linear regressions repeatedly.
We deﬁned a sufﬁciently ﬁne grid of potential threshold values
spot with 0 6 spot < maximum of the concentration c. This grid was
chosen as a set of equidistant test values spot across the empirical
distribution of the FA concentrations c among all animals. In all
analyses the grid of potential thresholds for concentration of expo-
sure was given by spot from 0 ppm to 15 ppm in steps of 0.1 ppm. A
modiﬁed concentration c(spot) was calculated for each animal and
each value of spot by compressing the concentration data (moving
it to the left by spot but not beyond zero):
cðspotÞ ¼ c  spot if c  spot and cðspotÞ ¼ 0 if c < spot ð1Þ
We used the log of ULLI or log of LI as the response y in model-
ling and ﬁtted linear regression models to these data (one model
for every value spot of the grid, 151 regression models per thresh-
old analysis). Because some rats were assigned zero ULLI or LI val-
ues, we added a small offset +0.01 to the response values to avoid
an undeﬁned logarithm. This offset was chosen as the smallest
meaningful change in y. The expectation of the transformed index
was ﬁtted as given in Eq. (2):
logðyþ 0:01Þ ¼ b cðspotÞ þ d durationþ constant ð2Þ
The likelihood proﬁle of these models was used to derive point esti-
mates and 95%-conﬁdence interval (CI) estimates for the concentra-
tion threshold. The best ﬁt identiﬁed the optimal threshold value
point estimate s among all spot. The likelihood proﬁle of these
models was also used to identify the point of the ﬁrst signiﬁcant
increase of the index above background (LOAEL). This point
was identiﬁed by comparing the likelihood ratio statistic
with chi2(95%) = 3.84. The statistical analysis is given in Online
Appendix 2.
Table 2
NOAECs/LOAECs for cell proliferation in different studies.
Study Labelling method Calculation
of
Exposure duration NOAEC/
LOAEC
Nasal sites
reported/
investigated
Wilmer et al. (1989) 3H-thymidine; ip injection, once LI 3 days; 13 weeks 2/4a 1/3
Monticello et al. (1991) 3H-thymidine; ip injection, once ULLI 1,4,9 days, 6 weeks 2/6 5/5
Casanova et al. (1994) 14C incorporation into DNA after inhalation of
[14C]FA
11 weeks + 4 days pre-
exposure
2/6 2/2
Monticello et al. (1996) 3H-thymidine; 5 days osmotic pump ULLI 3, 6, 12, 18 months 6/10 7/7
Andersen et al. (2008) BrdU; 3 days osmotic pump ULLI/LI 5 days; 3 weeks 2/6; 2/6 6/6
Andersen et al. (2010) BrdU; 3 days osmotic pump ULLI/LIb 1 week; 4 weeks; 13 weeks 6/10; 2/6; 6/10 2/6
Meng et al. (2010) BrdU; 3 days osmotic pump LI 13 (0.7/2c)6/10 1
Speit et al. (2011) BrdU; 3 days osmotic pump ULLI 4 weeks 2/6 7/7
a Numerical, but not statistically signiﬁcant increase.
b ULLI and LI were calculated, but only ULLI data reported.
c 2 ppm stated in RAC opinion to be the LOAEC based on numerical increase.
Table 3
Dependency of ULLI on duration of exposure at 6 and 15 ppm for the anterior lateral meatus (alm) and the medial maxilloturbinate (mmt) according to Monticello et al. (1991,
1996).
Exposure duration 1 day 4 days 9 days 6 weeks 3 months 6 months 12 months 18 months
Monticello (1991) Monticello (1996)
alm
0 ppm 2.16 1.46 1.44 0.99 10.11 11.14 8.28 5.74
6 ppm 16.86 30.51 23.51 14.41 15.78 7.98 6.24 3.51
15 ppm 12.68 25.78 24.57 28.74 93.22 65.89 74.99 34.62
mmt
0 ppm 2.49 1.36 1.38 1.02 7.84 17.95 7.85 5.58
6 ppm 18.15 25.03 22.54 16.32 9.23 10.18 6.22 5.03
15 ppm 5.31 19.39 28.71 25.10 115.19 101.97 66.64 63.11
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icant elevations above background levels of LI and ULLI could not
be found if the formaldehyde exposure was lower than 4 ppm for
LI and 3.5 ppm for ULLI. This analysis is preferable to the approach
of RAC by simply inspecting the single data points because of the
limited number of rats in each group. In addition, the combined
analysis took account of a potential impact of duration of exposure
by adjusting for this covariate. The ﬁndings from the single group
analyses were consistent with the combined evaluation based on
all 144 rats simultaneously. Thus, the LOAEC for LI is 4 ppm and
for ULLI 3.5 ppm.
In summary, based on the broad inherent variability of the cell
replication data reported by Meng et al. (2010), a LOAEC/NOAEC
decision must acknowledge all relevant studies showing consis-
tently a NOAEC at 2 ppm, in several studies even at 6 ppm. The
statistical analysis of the complete dataset and not only of the sub-
set used by RAC gave LOAECs for cell proliferation in the range of
3.5–4 ppm. Therefore the assumption in the RAC opinion that
2 ppm is a LOAEC cannot be justiﬁed.
5. Discussion and conclusion
On November 30, 2012 the Committee for Risk Assessment of
the European Chemicals Agency adopted an opinion proposing
the harmonised Classiﬁcation and Labelling at the EU level for
formaldehyde (RAC, 2012). The RAC stated that 2 ppm FA represent
a Lowest Observed Adverse Effect Concentration (LOAEC) for devel-
opment of polypoid adenomas, histopathological lesions and cell
proliferation. These interpretations were critically assessed here.
High FA concentrations (P10 ppm) may not only lead to SCC
but also to PA. PA seems to be a tumour type on its own, not relatedto SCC based on a comparison of the locations and indicated by the
histopathological features of PA and SCC. But the heterogeneous
diagnoses (papilloma, polyp, PA) and missing clear histomorpho-
logical descriptions in some of the relatively old studies do not
allow a ﬁnal decision which may only be possible after reassess-
ment of the histological slides using standardized and harmonized
internationally-accepted nomenclature according to the published
INHAND project. Although the occurrence of PAs is not reported in
the historical database of inhalation studies of NTP (2013) they
may occur spontaneously more often than generally assumed pro-
vided the nasal cavities are investigated in comparable details. By
the original statistical analysis of Kerns et al. (1983) a ﬁrm conclu-
sion regarding the NOAEC of PAs is not possible. A new statistical
analysis showed convincingly that reliable NOAECs/LOAECs could
not be derived for an exposure range up to 6 ppm from the data
available today.
The LOAEC for histopathological lesions is 2 ppm as described
by RAC (2012) but based on all studies available a NOAEC of
1 ppm can be derived. The heterogeneous diagnoses and the miss-
ing histomorphological features of the lesions found at 2 ppm do
not allow a ﬁrm conclusion whether or not they are to be regarded
as a preneoplastic response. Again, a pathology peer review may
provide a solid answer. But their location in comparison with that
of SCC speaks against a direct relation to neoplasms.
A LOAEC for cell replication, a potential precursor event, cannot
rely solely on the numerical increase at 2 ppm in a subset of data
(Meng et al., 2010) taken from a larger study (Andersen et al.,
2010). A LOAEC/NOAEC decision must acknowledge all relevant
studies that consistently found a NOAEC at 2 ppm, in several stud-
ies even at 6 ppm. In addition, a statistical analysis showed that the
LOAECs for cell proliferation are in the range of 3.5–4 ppm.
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liferation are published in the two online Appendices to this paper
and were available to RAC during their discussions. It is unclear
why RAC did not consider this information when coming to its con-
clusions about the LOAECs for formaldehyde.
In summary, we challenge the assessments of RAC and conclude
that
- PA are not related to development of SCC and the data do not
allow to deﬁne a LOAEC or NOAEC.
- For histopathological alterations a NOAEC of 1 ppm can be
derived and lesions at 2 ppm are not related to SCC
development.
- For cell replication the total database clearly justiﬁes a NOAEC
of 2 ppm and LOAECs of 3 ppm to 4 ppm.
The discrepancies to the RAC opinion may seem rather small
taking into consideration the often much larger uncertainties sur-
rounding many toxicological datasets and risk assessments. Never-
theless such a detailed evaluation is necessary taking into
consideration that an extremely broad database of FA is available
for a sound derivation of NOAECs/LOAECs.
Any opinion of RAC as a highly respected and inﬂuential body
may have important potential impacts and leverages on other reg-
ulatory processes such as setting of exposure limits for the work-
place and indoor air and the huge economic impact thereof even
by an additional factor of 2.
In summary, our detailed reassessment of the extremely broad
database does not support the assessments of RAC (2012) that
2 ppm FA represent a LOAEC for tumour development, histopathol-
ogical lesions and cell proliferation. Rather, the available data
clearly indicate NOAECs for histopathological lesions and cell pro-
liferation of 1 ppm and 2 ppm, respectively.
Conﬂict of interest
HPG and PM are members of the Science Advisory Group of For-
macare, a sector group of the European Chemical Industry Council
(Ceﬁc) see http://www.formacare.org/. SG is employed of BASF SE,
a company that manufactures formaldehyde. The authors have sole
responsibility for the content and the writing of the paper. The
interpretation and views expressed in the paper are not necessarily
those of the author’s employers or association.
Acknowledgments
We like to thank Martina Dammann for her support with data
preparation for statistical analysis (BASF SE, Germany). The ﬁnan-
cial support of Formacare is gratefully acknowledged.
Appendix A. Supplementary data
Supplementary data associated with this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.yrtph.
2014.07.016.
References
Andersen, M.E., Clewell, H.J., Bermudez, E., Willson, G.A., Thomas, R.S., 2008.
Genomic signatures and dose-dependent transitions in nasal epithelial
responses to inhaled formaldehyde in the rat. Toxicol. Sci. 105, 368–383.
Andersen, M.E., Clewell, H.J., Bermudez, E., Dodd, D.E., Willson, G.A., Campbell, J.L.,
Thomas, R.S., 2010. Formaldehyde: integrating dosimetry, cytotoxicity and
genomics to understand dose-dependent transitions for an endogenous
compound. Toxicol. Sci. 118, 716–731.
Appelman, L.M., Woutersen, R.A., Zwart, A., Falke, H.E., Feron, V.J., 1988. One-year
inhalation toxicity study of formaldehyde in male rats with damaged or
undamaged nasal mucosa. J. Appl. Toxicol. 8, 85–90.Battelle, 1981. Final report on a chronic inhalation toxicology study in rats and mice
exposed to formaldehyde. Battelle Columbus Laboratories, CIIT Docket 10922.
Casanova, M., Morgan, K.T., Gross, E.A., Moss, O.R., Heck, H., 1994. DNA-protein
cross-links and cell replication at speciﬁc sites in the nose of F344 rats exposed
subchronically to formaldehyde. Fund. Appl. Toxicol. 23, 525–536.
Feron, V.J., Bruyntjes, J.P., Woutersen, R.A., Immel, H.R., Appelman, L.M., 1988. Nasal
tumours in rats after short-term exposure to a cytotoxic concentration of
formaldehyde. Cancer Lett. 39, 101–111.
Greenland, S., Schwartzbaum, J.A., Finkle, W.D., 2000. Problems due to small
samples and sparse data in conditional logistic regression analysis. Am. J.
Epidemiol. 151, 531–539.
Kamata, E., Nakadate, M., Uchida, O., Ogawa, Y., Suzuki, S., Kaneko, T., Saito, M.,
Kurokawa, Y., 1997. Results of a 28-month chronic inhalation toxicity study of
formaldehyde in male Fisher 344 rats. J. Toxicol. Sci. 22, 239–254.
Kerns, W.D., Pavkov, K.L., Donofrio, D.J., Gralla, E.J., Swenberg, J.A., 1983.
Carcinogenicity of formaldehyde in rats and mice after long-term inhalation
exposure. Cancer Res. 43, 4382–4392.
Kerns, W.D., 1985. Polypoid adenoma, nasal mucosa, rat. In: Jones, T.C., Mohr, U.,
Hunt, R.D. (Eds.), Respiratory System. Springer Verlag, Berlin, Heidelberg, New
York, Tokyo, pp. 41–47.
Lomax, L.G., Krivanek, N.D., Frame, S.R., 1997. Chronic inhalation toxicity and
oncogenicity of methyl methacrylate in rats and hamsters. Food Chem. Toxicol.
35, 393–407.
Meng, F., Bermudez, E., McKinzie, P.B., Andersen, M.E., Clewell, H.J., Parsons, B.L.,
2010. Measurement of tumor-associated mutations in the nasal mucosa of rats
exposed to varying doses of formaldehyde. Reg. Toxicol. Pharmacol. 57, 274–
283.
Miller, R.R., Young, J.T., Kociba, R.J., Keyes, D.G., Bodner, K.M., Calhoun, L.L., Ayres,
J.A., 1985. Chronic toxicity and oncogenicity bioassay of inhaled ethyl acrylate
in Fischer 344 rats and B6C3F1 mice. Drug Chem. Toxicol. 8, 1–42.
Monticello, T.M., Morgan, K.T., Hurtt, M.E., 1990. Unit length as the denominator for
quantitation of cell proliferation in nasal epithelia. Toxicol. Pathol. 18, 24–29.
Monticello, T.M., Miller, F.J., Morgan, K.T., 1991. Regional increases in rat nasal
epithelial cell proliferation following acute and subchronic inhalation of
formaldehyde. Toxicol. Appl. Pharmacol. 111, 409–421.
Monticello, T.M., Swenberg, J.A., Gross, E.A., Leininger, J.R., Kimbell, J.S., Seilkop, S.,
Starr, T.B., Gibson, J.E., Morgan, K.T., 1996. Correlation of regional and nonlinear
formaldehyde-induced nasal cancer with proliferating populations of cells.
Cancer Res. 56, 1012–1022.
Morfeld, P., Albrecht, C., Drommer, W., Borm, P.J.A., 2006. Dose–response and
threshold analysis of tumour prevalence after intratracheal instillation of six
types of low and high surface area particles in a chronic rat experiment. Inhal.
Toxicol. 18, 215–225.
Morfeld, P., Mundt, K.A., Taeger, D., Guldner, K., Steinig, O., Miller, B.G., 2013.
Threshold value estimation for respirable quartz dust exposure and silicosis
incidence among workers in the German porcelain industry. J. Occup. Environ.
Med. 55, 1027–1034.
Morgan, K.T., Jiang, X.Z., Starr, T.B., Kerns, W.D., 1986. More precise localization of
nasal tumors associated with chronic exposure of F344 rats to formaldehyde
gas. Toxicol. Appl. Pharmacol. 82, 264–271.
Nielsen, G.D., Wolkoff, P., 2010. Cancer effects of formaldehyde: a proposal for an
indoor air guideline value. Arch. Toxicol. 84, 423–446.
NTP, 2013. http://ntp.niehs.nih.gov/?objectid=92E61F1B-F1F6-975E-7D3BED551F0
7DC0A.
RAC, 2012. Opinion Proposing Harmonised Classiﬁcation and Labelling at EU Level
of Formaldehyde, http://echa.europa.eu/documents/10162/254a73cf-ff8d-
4bf4-95d1-109f13ef0f5a (adopted 30.09.12).
Renne, R., Brix, A., Harkema, J., Herbert, R., Kittel, B., Lewis, D., March, T., Nagano, K.,
Pino, M., Rittinghausen, S., Rosenbruch, M., Tellier, P., Wohrmann, T., 2009.
Proliferative and nonproliferative lesions of the rat and mouse respiratory tract.
Toxicol. Pathol. 37 (7 Suppl.), 5s–73s.
Rusch, G.M., Clary, J.J., Rinehart, W.E., Bolte, H.F., 1983. A 26-week inhalation
toxicity study with formaldehyde in the monkey, rat and hamster. Toxicol. Appl.
Pharmacol. 68, 329–343.
Sellakumar, A.R., Snyder, C.A., Solomon, J.J., Albert, R.E., 1985. Carcinogenicity of
formaldehyde and hydrogen chloride in the rat. Toxicol. Appl. Pharmacol. 81,
401–406.
Speit, G., Schütz, P., Weber, I., Ma-Hock, L., Kaufmann, W., Gelbke, H.P., Durrer, S.,
2011. Analysis of micronuclei, histopathological changes and cell proliferation
in nasal epithelium cells of rats after exposure to formaldehyde by inhalation.
Mut. Res. 721, 127–135.
Subbiah, M., Srinivasan, M.R., 2008. Classiﬁcation of 22 sparse data sets with zero
cells. Stat. Probab. Lett. 78, 3212–3215.
Swenberg, J.A., Kerns, W.D., Mitchell, R.A., Gralla, E.J., Pavkov, K.L., 1980. Induction
of squamous cell carcinomas of the rat nasal cavity by inhalation exposure to
formaldehyde vapor. Cancer Res. 40, 3398–3402.
Swenberg, J.A., Barrow, C.S., Boreiko, C.J., Heck, H.D., Levine, R.J., Morgan, K.T.,
Starr, T.B., 1983. Non-linear biological responses to formaldehyde and their
implications for carcinogenic risk assessment. Carcinogenesis 4, 945–
952.
Hamner, 2007. Studies to improve the scientiﬁc basis for a biologically-based cancer
risk assessment: genomic analysis of rat nasal tissues following formaldehyde
inhalation for 13 weeks. Contract No.: 07007. The Hamner Institutes for Health
Sciences, 6 Davis Drive, Research Triangle Park, NC 27709-2137.
Ulm, K., 1991. A statistical method for assessing a threshold in epidemiological
studies. Stat. Med. Mar. 10, 341–349.
348 H.-P. Gelbke et al. / Regulatory Toxicology and Pharmacology 70 (2014) 340–348Wilmer, J.W.G.M., Woutersen, R.A., Appelman, L.M., Leeman, W.R., Feron, V.J., 1989.
Subchronic (13 week) inhalation toxicity study of formaldehyde in male rats:
8-hour intermittent versus 8-hour continuous exposures. Toxicol. Lett. 47, 287–
293.
Woutersen, R.A., Feron, V.J., 1989. Localization of nasal tumours in rats exposed to
acetaldehyde or formaldehyde. In: Feron, V.J., Bosland, M.C. (Eds.), NasalCarcinogenesis in Rodents: Relevance to Human Health Risk. Proceedings of the
TNO-CIVO/NYU Nose Symposium, Veldhoven, Netherlands, 24–28 October
1988, Pudoc Wageningen, pp. 70–75.
Woutersen, R.A., van Garderen-Hoetmer, A., Bruijntjes, J.P., Zwart, A., Feron, V.J.,
1989. Nasal tumours in rats after severe injury to the nasal mucosa and
prolonged exposure to 10 ppm formaldehyde. J. Appl. Toxicol. 9, 39–46.
